Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer

Oncogenic KRAS mutation plays a key role in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis with nearly 95% of PDAC harboring mutation-activated KRAS, which has been considered an undruggable target. Doublecortin-like kinase 1 (DCLK1) is often overexpressed in pancreatic cancer, and recent stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Dongfeng, Weygant, Nathaniel, Yao, Jiannan, Chandrakesan, Parthasarathy, Berry, William L., May, Randal, Pitts, Kamille, Husain, Sanam, Lightfoot, Stan, Li, Min, Wang, Timothy C., An, Guangyu, Clendenin, Cynthia, Stanger, Ben Z., Houchen, Courtney W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699308/
https://www.ncbi.nlm.nih.gov/pubmed/31467540
http://dx.doi.org/10.1155/2019/6402925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699308/
https://www.ncbi.nlm.nih.gov/pubmed/31467540
http://dx.doi.org/10.1155/2019/6402925

Ejemplares similares